INDICLOR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDICLOR is an injectable diagnostic or therapeutic agent approved by GE HealthCare in 1992 with an unknown mechanism of action and indication profile. The product's exact pharmacologic class and therapeutic target remain unspecified in available data.
LOE Approaching
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30/100), signaling potential team consolidation and transition focus to line extensions or managed exit.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
INDICLOR linked roles emphasize technical and operational expertise (907 open positions) across Engineering, Manufacturing, and Finance—reflecting a mature product requiring supply chain optimization and cost management. Career trajectory favors operations-focused professionals navigating the LOE transition rather than commercial-expansion roles.
Data ManagerDualer Student (w/m/d) Betriebswirtschaftslehre
Worked on INDICLOR at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.